Widely used:Recently Viewed
Clear AllQuality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
$16 Mln
P/E Ratio
--
P/B Ratio
4.42
Industry P/E
--
Debt to Equity
0
ROE
-5.37 %
ROCE
--
Div. Yield
0 %
Book Value
--
EPS
--
CFO
$-56.85 Mln
EBITDA
$-23.84 Mln
Net Profit
$-46.83 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Briacell Therapeutics Corp (BCTX)
| -22.12 | 47.65 | 8.35 | -81.03 | -60.93 | -44.32 | -41.07 |
|
BSE Sensex
| 1.99 | 3.77 | 4.29 | 8.22 | 11.74 | 20.16 | 11.15 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
|
|---|---|---|---|---|---|---|---|
|
Briacell Therapeutics Corp (BCTX)
| 35.16 | -47.22 | 98.56 | -57.62 | -37.52 | -47.38 | -33.13 |
|
S&P Small-Cap 600
| 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 | 11.73 |
|
BSE Sensex
| 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 | 27.91 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal... Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers. It has a license agreement with the University of Maryland, Baltimore County to develop and commercialize soluble CD80 as a biologic agent for the treatment of cancer. BriaCell Therapeutics Corp. is based in West Vancouver, Canada. Address: Bellevue Centre, West Vancouver, BC, Canada, V7T 2X1 Read more
CEO, President & Director
Dr. William V. Williams M.D.
CEO, President & Director
Dr. William V. Williams M.D.
Headquarters
West Vancouver, BC
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Briacell Therapeutics Corp (BCTX) stood at $ 15 Mln as on 31-Jan-25
The share price of Briacell Therapeutics Corp (BCTX) is $6.60 (NASDAQ) as of 24-Apr-2025 12:43 EDT. Briacell Therapeutics Corp (BCTX) has given a return of -60.93% in the last 3 years.
Briacell Therapeutics Corp (BCTX) has a market capitalisation of $ 16 Mln as on 22-Apr-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Briacell Therapeutics Corp (BCTX) is 4.42 times as on 22-Apr-2025, a 0% premium to its peers’ median range of 4.42 times.
Since, TTM earnings of Briacell Therapeutics Corp (BCTX) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Briacell Therapeutics Corp (BCTX) and enter the required number of quantities and click on buy to purchase the shares of Briacell Therapeutics Corp (BCTX).
BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers. It has a license agreement with the University of Maryland, Baltimore County to develop and commercialize soluble CD80 as a biologic agent for the treatment of cancer. BriaCell Therapeutics Corp. is based in West Vancouver, Canada. Address: Bellevue Centre, West Vancouver, BC, Canada, V7T 2X1
The CEO & director of Dr. William V. Williams M.D.. is Briacell Therapeutics Corp (BCTX), and CFO & Sr. VP is Dr. William V. Williams M.D..
There is no promoter pledging in Briacell Therapeutics Corp (BCTX).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|
| Briacell Therapeutics Corp (BCTX) | Ratios |
|---|---|
|
Return on equity(%)
|
--
|
|
Operating margin(%)
|
-135837.45
|
|
Net Margin(%)
|
-51131.41
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Briacell Therapeutics Corp (BCTX) was $0 Mln.
$1.17
(
